Ramelteon in the treatment of chronic insomnia: Systematic review and meta-analysis

International Journal of Clinical Practice

Volumn 66, Issue 9, 2012, Pages 867-873

  Liu, J ^a   Wang, L N ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMELTEON;

ADULT; AGED; CHRONIC DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; PARALLEL DESIGN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SLEEP PARAMETERS; SLEEP TIME; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865201575     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02987.x     Document Type: Review

References (45)

1. National Institutes of Health,. National Institutes of Health State of the Science Conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005. Sleep 2005; 28: 1049-57.
2. Kim K, Uchiyama M, Okawa M, et al. An epidemiological study of insomnia among the Japanese general population. Sleep 2000; 23: 41-7. (Pubitemid 30080720)
3. Leger D, Guilleminault C, Dreyfus JP, et al. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000; 9: 35-42. (Pubitemid 30195291)
4. Ohayon MM, Caulet M, Guilleminault C,. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997; 20: 715-23. (Pubitemid 27506202)
5. Ohayon MM, Zulley J, Guilleminault C, et al. How age and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc 2001; 49: 360-6. (Pubitemid 32390866)
6. Montgomery P, Dennis J,. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003; Issue 1: CD003161.
7. Walsh JK, Engelhardt CL,. The direct economic costs of insomnia in the United States for 1995. Sleep 1999; 22 (Suppl. 2): S386-93. (Pubitemid 29293500)
8. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331: 1169.
9. Golombok S, Moodley P, Lader M,. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18: 365-74.
10. Morgan K, Tomeny M,. Benzodiazepine withdrawal and rebound insomnia. Acta Psychiatr Scand 1989; 80: 297-8.
11. Liu J, Wang L,. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2011; Issue 1: CD008502.
12. Vermeeren A, Coenen AM,. Effects of the use of hypnotics on cognition. Prog Brain Res 2011; 190: 89-103.
13. Sateia MJ, Nowell PD,. Insomnia. Lancet 2004; 364: 1959-73. (Pubitemid 39574600)
14. Poyares D, Guilleminault C, Ohayon MM, et al. Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res 2004; 38: 327-34. (Pubitemid 38299171)
15. Dubocovich ML, Yun K, Al-Ghoul WM, et al. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998; 12: 1211-20. (Pubitemid 28418951)
16. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301-10. (Pubitemid 40208266)
17. Johnson MW, Suess PE, Griffiths RR,. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006; 63: 1149-57. (Pubitemid 44500632)
18. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7: 17-24. (Pubitemid 43033540)
19. Richardson GS, Zammit G, Wang-Weigand S, et al. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 2009; 70: 467-76.
20. Griffiths R, Suess P, Johnson M,. Ramelteon and triazolam in humans: behavioral effects and abuse potential. Sleep 2005; 28: A44.
21. Mets MA, de Vries JM, de Senerpont Domis LM, et al. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011; 34: 1327-34.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (text revision). Washington, DC: American Psychiatric Association, 2000.
23. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.
24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. (Pubitemid 27387172)
25. Uchiyama M, Hamamura M, Kuwano T, et al. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med 2011; 12: 119-26.
26. Uchimura N, Ogawa A, Hamamura M, et al. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study. Expert Rev Neurother 2011; 11: 215-24.
27. Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009; 32: 351-60.
28. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3: 495-504. (Pubitemid 47378253)
29. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7: 312-8. (Pubitemid 43792892)
30. Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007; 23: 1005-14. (Pubitemid 46799582)
31. Zammit G, Wang-Weigand S, Rosenthal M, et al. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med 2009; 5: 34-40.
32. Gooneratne NS, Gehrman P, Gurubhagavatula I, et al. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. J Clin Sleep Med 2010; 6: 572-80.
33. Gross PK, Nourse R, Wasser TE,. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med 2009; 5: 28-33.
34. Karim A, Tolbert D, Cao C,. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006; 46: 140-8. (Pubitemid 43146444)
35. Kryger M, Roth T, Wang-Weigand S, et al. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath 2009; 13: 79-84.
36. Kryger M, Wang-Weigand S, Roth T,. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath 2007; 11: 159-64. (Pubitemid 47307844)
37. McElroy SL, Winstanley EL, Martens B, et al. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2011; 26: 48-53.
38. Markwald RR, Lee-Chiong TL, Burke TM, et al. Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep. Sleep 2010; 33: 825-31.
39. Zee PC, Wang-Weigand S, Wright KP Jr, et al. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med 2010; 11: 525-33.
40. Zammit G, Schwartz H, Roth T, et al. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med 2009; 10: 55-9.
41. Roth T, Stubbs C, Walsh JK,. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28: 303-7. (Pubitemid 40315565)
42. Richardson G, Wang-Weigand S,. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009; 24: 103-11.
43. Mini LJ, Wang-Weigand S, Zhang J,. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007; 5: 177-84. (Pubitemid 350048506)
44. Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995; 18: 425-32.
45. Wang-Weigand S, McCue M, Ogrinc F, et al. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. Curr Med Res Opin 2009; 25: 1209-13.